Core Viewpoint - The article discusses the significant cash dividend announced by Sinovac Biotech, which will distribute $55 per share to shareholders, resulting in an astonishing dividend yield of 850% based on its last trading price of $6.47 before suspension [1][2][8]. Group 1: Dividend Announcement - On June 18, Sinovac Biotech's board announced a special cash dividend of $55 per share to be paid on July 7, along with plans for additional dividends of $19 and a potential third dividend ranging from $20 to $50 per share [4][8]. - The dividend yield of 850% is calculated based on the stock price of $6.47 prior to the suspension, highlighting the extraordinary nature of this payout [2][8]. Group 2: Financial Performance - Sinovac Biotech, a well-known biotechnology and vaccine production company, reported a net profit of $44.92 million in 2019 before the COVID-19 pandemic [11]. - The company saw a dramatic increase in revenue during the pandemic, with total revenue reaching $19.375 billion in 2021, a 3694% increase year-over-year, primarily driven by COVID-19 vaccine sales [13]. - However, post-pandemic, the company's revenue plummeted to $1.5 billion in 2022, a 92% decrease, and it reported a net loss of $99.91 million in 2023, a 187% decline year-over-year [14]. Group 3: Governance Issues - Sinovac Biotech has been embroiled in a seven-year power struggle, which began in 2015 between its founder and a rival shareholder, leading to a series of legal battles and governance disputes [15][17]. - The board's composition was challenged, and a recent ruling by the UK Privy Council replaced several board members, raising questions about the legitimacy of the current board [18]. - The ongoing governance issues have led to speculation that the large dividend payout may be a strategy to weaken potential opposition by depleting the company's cash reserves [18].

无独有偶，国家卫健委副主任、国家疾控局局长沈洪兵在近期举办的2025年疫苗与健康大会上也透 露，国家疾控局准备做一个到2030年的五年规划，逐步缩小国内免疫规划与国际差距，逐步纳入需 要纳入的疫苗。 根据沈洪兵对未来动态调整国家免疫规划的设想：一是新增疫苗的种类。国际普遍共识的、疾病负担 重、成本效益高、疫苗产能满足需求、财政可负担的，要尽快纳入。二是优化现有疫苗免疫程序。根 据流行特点、防控目标变化、疫苗特性等进行优化。三是探索疫苗退出程序。不属于全人群普遍接种 的疫苗，现有疫苗不适应疾病防控需要等情况，也要考虑疫苗退出，或改为储备疫苗。 2025.04. 24 本文字数：2701，阅读时长大约4分钟 作者 | 第一财经 吴斯旻 我国国家免疫规划已有17年没有纳入新疫苗。时值"世界免疫周"，国家疾控局近日频频发声，释放 出国家免疫规划策略将"动态调整""提质扩容"的信号。多名受访业界人士认为，国家免疫规划疫苗扩 容优化已至关键节点。 国家疾控局卫生免疫司副司长李筱翠近日在国家疾控局召开的一场新闻发布会上介绍说，当前，传染 病仍然是全球面临的公共卫生风险，需要我们不断加强疫苗接种的普及和推广。为此，在当前和今 ...

Core Points - Vaccination is the most effective and convenient method for preventing infectious diseases such as measles, hand-foot-mouth disease, and mumps [1] - The chief expert from the Chinese Center for Disease Control and Prevention, Wang Huaqing, emphasized the importance of vaccination and hygiene practices to prevent the spread of these diseases [1][2] Group 1: Vaccination Recommendations - Measles and mumps can be prevented through the administration of the measles-mumps-rubella (MMR) vaccine [1] - The EV71 vaccine is effective in preventing hand-foot-mouth disease caused by the EV71 enterovirus [1] - Timely vaccination is recommended for children at 8 months and 18 months of age to protect their health [2] Group 2: Preventive Measures - Maintaining good hygiene habits is crucial for disease prevention [1] - Regular ventilation and keeping the air fresh are important preventive measures [1] - During epidemic seasons, it is advisable to avoid crowded places with children [1] - Avoiding contact with infected individuals during the acute phase of the disease is recommended [1] - Health monitoring for children, including morning checks in kindergartens and primary schools, is essential [1]